diseas
bd
chronic
system
inflammatori
diseas
unclear
etiopathogenesi
gene
variant
cc
chemokin
receptor
type
patient
bd
identifi
associ
howev
protein
express
patient
bd
mous
model
remain
unclear
cc
chemokin
receptor
type
express
cell
immun
system
includ
lymphocyt
monocyt
neutrophil
dendrit
involv
host
defens
hematopoiesi
helper
type
cell
balanc
express
correl
variou
inflammatori
diseas
includ
rheumatoid
lupu
knockout
mice
show
reduc
pulmonari
prolong
allograft
polymorph
might
gener
risk
factor
autoimmun
inflammatori
diseas
antagonist
use
clinic
trial
treat
multipl
sclerosi
psoriasi
rheumatoid
herp
simplex
viru
hsv
report
etiolog
factor
mous
model
inflammatori
bd
develop
use
variou
object
present
studi
determin
express
mice
inflammatori
bd
symptom
investig
whether
regul
ligand
agonist
antagonist
flow
cytometri
use
examin
frequenc
cell
surfac
cytoplasm
lymph
node
ln
cell
peripher
blood
mononuclear
cell
pbmc
result
demonstr
correl
surfac
express
pbmc
sever
bd
symptom
mice
male
icr
mice
week
old
infect
hsv
type
unitsml
f
strain
grown
vero
cell
describ
viru
inocul
twice
mice
frequenc
day
second
hsv
inocul
mice
observ
week
week
anim
handl
accord
guidelin
provid
institut
anim
care
use
committe
ajou
univers
school
medicin
among
mice
infect
hsv
develop
symptom
includ
skin
ulcer
skin
pustul
genit
ulcer
erythema
oral
ulcer
ear
inflamm
arthriti
genit
ulcer
red
eye
left
right
reduc
vision
left
right
weight
loss
facial
swell
oral
genit
skin
ulcer
eye
symptom
classifi
major
symptom
symptom
identifi
minor
symptom
mice
display
one
major
one
minor
symptom
diagnos
bd
symptom
score
assign
singl
point
sum
symptom
score
use
determin
sever
bd
disappear
symptom
decreas
lesion
size
classifi
symptom
improv
diseas
sever
score
bd
calcul
accord
bd
activ
index
outlin
bd
activ
form
wwwbehcetwspdfbehcetsdiseaseactivityformpdf
asymptomat
healthi
mice
bdn
mice
serv
control
group
describ
previous
peripher
blood
mononuclear
cell
ln
cell
isol
mice
erythrocyt
elimin
solut
wash
salin
pb
follow
surfac
stain
cell
mous
antibodi
cat
r
system
minneapoli
mn
min
dark
intracytoplasm
stain
cell
fix
intracytoplasm
fixat
buffer
min
room
temperatur
wash
twice
permeabil
buffer
cell
stain
antibodi
follow
analysi
cell
flow
cytomet
fac
canto
ii
becton
dickinson
san
jose
ca
fresh
pbmc
wash
twice
cold
pb
lyze
lysi
buffer
mm
ph
nacl
mm
edta
triton
aprotinin
leupeptin
mm
phenylmethylsulphonyl
fluorid
protein
lysat
electrophores
sodium
dodecyl
gel
protein
transfer
onto
nitrocellulos
membran
protran
ge
healthcar
life
scienc
chicago
il
usa
subject
immunoblot
analysi
use
antibodi
immunoblot
develop
enhanc
chemiluminesc
system
ge
healthcar
life
scienc
antibodi
purchas
r
system
glyceraldehyd
dehydrogenas
gapdh
antibodi
santa
cruz
biotechnolog
inc
dalla
tx
normal
bd
mice
treat
vivo
pb
pgmouseday
cat
prospecbio
israel
factor
pgmouseday
cat
prospecbio
chemokin
cc
motif
ligand
pgmouseday
cat
prospecbio
antibodi
ngmouseday
cat
r
system
five
consecut
day
intraperiton
administr
normal
mice
week
old
pbmc
ln
cell
isol
hr
last
medic
analysi
cell
flow
cytometri
antagonist
cat
st
loui
mo
intraperiton
administ
normal
bd
mice
mgmous
three
time
everi
day
bd
symptom
observ
treatment
imag
obtain
document
chang
mice
treat
oral
pb
colchicin
pentoxifyllin
five
consecut
day
chang
symptom
monitor
hr
last
medic
mice
kill
intramuscular
inject
hind
leg
ketaminexylazin
cocktail
mgkg
ketamin
mgkg
xylazin
pbmc
ln
cell
isol
analysi
cell
patient
popul
consist
patient
bd
present
first
time
monitor
depart
dermatolog
ajou
univers
hospit
sampl
patient
bd
random
patient
first
arriv
clinic
characterist
therapeut
histori
patient
shown
tabl
accord
intern
studi
group
bd
criteria
presenc
two
follow
symptom
addit
recurr
oral
ulcer
consid
bd
diagnosi
recurr
genit
ulcer
cutan
erythema
nodosum
vascul
arthriti
uveiti
andor
posit
pathergi
test
diseas
sever
score
calcul
diseas
current
activ
form
http
wwwbehcetdiseasesocietyorgbehcetwsdatauploadsfilesbehcetsdiseaseactivityformpdf
patient
activ
bd
n
men
one
woman
year
enrol
gender
differ
among
bd
patient
mucocutan
manifest
inconsist
among
differ
inform
consent
obtain
patient
studi
healthi
control
group
n
year
compris
one
man
women
serum
provid
biobank
ajou
univers
hospit
member
korea
biobank
network
studi
approv
ethic
committe
ajou
univers
medic
center
institut
review
board
experi
conduct
accord
institut
review
board
permit
protocol
peripher
blood
collect
test
tube
centrifug
g
min
supernat
store
use
level
measur
plasma
use
commerci
immunosorb
assay
elisa
kit
cat
thermo
fisher
scientif
waltham
follow
manufactur
instruct
elisa
analysi
sampl
appli
duplic
well
three
time
differ
elisa
plate
data
statist
analysi
compli
recommend
experiment
design
analysi
pharmacolog
flow
cytometr
analysi
perform
analyz
surfac
cytoplasm
cell
stain
antibodi
pbmc
ln
cell
isol
normal
n
bdn
n
bd
n
mice
frequenc
cell
surfac
pbmc
significantli
bd
mice
compar
normal
mice
versu
p
bdn
mice
versu
p
frequenc
cell
surfac
ln
cell
also
bd
mice
compar
normal
mice
versu
p
bdn
mice
versu
p
fig
frequenc
cytoplasm
stain
pbmc
significantli
lower
bd
mice
normal
mice
versu
p
bdn
mice
versu
p
frequenc
ln
cell
also
significantli
lower
bd
mice
normal
mice
versu
p
differ
frequenc
cell
bd
bdn
mice
versu
p
fig
repres
histogram
surfac
stain
result
present
fig
c
figur
show
western
blot
analysi
express
whole
pbmc
lysat
normal
bdn
bd
mice
n
group
express
ratio
compar
gapdh
differ
bdn
bd
mice
fig
n
mean
entir
amount
pbmc
correl
symptom
synergist
enhanc
known
therefor
administ
normal
bd
mice
determin
function
dose
mice
vivo
inject
normal
mice
intraperiton
follow
dose
pg
pg
hr
last
treatment
pbmc
isol
mice
flow
cytometri
measur
frequenc
cell
surfac
cytoplasm
mice
treat
pg
n
frequenc
surfac
cell
significantli
pbmc
compar
control
mice
n
versu
p
treatment
pg
n
affect
frequenc
cell
compar
control
mice
n
versu
p
treatment
pg
n
frequenc
cell
compar
control
mice
n
although
differ
statist
signific
versu
p
frequenc
cytoplasm
pbmc
slightli
increas
mice
treat
pg
pg
compar
control
mice
versu
p
versu
p
although
differ
statist
signific
fig
normal
mice
expos
pg
n
frequenc
surfac
pbmc
compar
control
mice
versu
p
mice
treat
pg
n
frequenc
cell
higher
compar
level
control
mice
n
versu
p
howev
differ
statist
signific
mice
treat
pg
n
show
frequenc
cell
similar
control
mice
n
cytoplasm
pbmc
frequenc
cell
mice
treat
pg
respect
significantli
p
differ
compar
pb
control
group
fig
accord
function
dose
normal
mice
pgmouseday
pgmouseday
administ
bd
mice
cell
five
consecut
day
treatment
bd
mice
pbmc
ln
cell
subject
surfac
cytoplasm
stain
fac
analysi
surfac
pbmc
frequenc
cell
bd
mice
treat
n
n
show
signific
compar
bd
mice
n
versu
pb
versu
p
versu
pb
versu
p
surfac
ln
cell
significantli
compar
bd
mice
versu
pb
versu
p
versu
pb
versu
p
fig
cytoplasm
pbmc
also
increas
treatment
versu
p
versu
p
compar
bd
mice
cytoplasm
cell
ln
increas
versu
p
frequenc
cytoplasm
ln
cell
chang
treatment
fig
frequenc
cell
normal
bd
mice
multipl
ligand
one
ligand
determin
whether
regul
intraperiton
inject
normal
mice
frequenc
pbmc
ln
cell
decreas
treatment
surfac
stain
pbmc
treatment
pg
n
significantli
decreas
frequenc
cell
compar
pb
control
n
versu
p
treatment
pg
decreas
frequenc
cell
although
decreas
signific
versu
p
surfac
stain
ln
cell
treatment
pg
n
significantli
frequenc
cell
compar
pb
control
n
versu
p
treatment
pg
n
result
similar
frequenc
cell
compar
control
mice
fig
frequenc
cytoplasm
pbmc
treatment
pg
significantli
decreas
p
p
compar
pb
control
cytoplasm
ln
cell
significantli
mice
treat
pg
p
pg
p
compar
control
mice
fig
histogram
surfac
cytoplasm
pbmc
treatment
present
fig
c
cell
bd
mice
pgday
administ
bd
mice
n
five
consecut
day
frequenc
surfac
pbmc
significantli
lower
compar
bd
mice
n
versu
p
frequenc
surfac
ln
cell
differ
treatment
fig
cytoplasm
ln
cell
significantli
treatment
compar
pb
control
versu
p
howev
express
chang
pbmc
cytoplasm
fig
treatment
deterior
bd
symptom
bd
mice
diseas
sever
score
increas
day
treatment
four
bd
mice
show
new
skin
ulcer
arthriti
remain
bd
mice
show
increas
ulcer
size
develop
antagonist
treat
sever
inflammatori
diseas
includ
rheumatoid
administ
bd
mice
bd
mice
n
show
surfac
pbmc
surfac
ln
cell
cytoplasm
pbmc
cytoplasm
ln
cell
bd
mice
play
role
cell
fig
b
normal
mice
mice
show
higher
frequenc
surfac
pbmc
normal
mice
versu
p
ln
cell
versu
p
inhibit
express
found
cytoplasm
pbmc
versu
pb
versu
p
fig
colchicin
pentoxifyllin
frequent
prescrib
medic
also
use
bd
determin
correl
express
two
agent
colchicin
n
pentoxifyllin
n
administ
normal
mice
surfac
express
pbmc
significantli
compar
normal
mice
n
colchicin
versu
pb
versu
p
pentoxifyllin
versu
pb
versu
p
colchicin
significantli
express
surfac
ln
cell
compar
normal
mice
versu
p
pentoxifyllin
also
express
compar
normal
mice
although
statist
signific
versu
p
fig
colchicin
pentoxifyllin
significantli
express
cytoplasm
pbmc
p
p
respect
compar
pb
control
cytoplasm
express
ln
cell
alter
colchicin
pentoxifyllin
treatment
fig
frequenc
cell
determin
bd
mice
treat
medic
treatment
colchicin
n
pentoxifyllin
n
significantli
surfac
express
pbmc
bd
mice
compar
bd
mice
n
versu
p
versu
p
respect
frequenc
surfac
ln
cell
also
increas
significantli
colchicin
pentoxifyllin
compar
bd
mice
versu
p
versu
p
respect
fig
cytoplasm
pbmc
treatment
colchicin
pentoxifyllin
increas
frequenc
cell
howev
pentoxifyllin
treatment
result
signific
increas
versu
p
colchicin
pentoxifyllin
affect
frequenc
cytoplasm
ln
cell
compar
bd
mice
fig
histogram
express
surfac
cytoplasm
pbmc
treatment
colchicin
pentoxifyllin
present
fig
e
result
show
frequenc
surfac
express
rather
cytoplasm
express
strongli
correl
regul
bd
symptom
determin
whether
regul
inhibit
antibodi
intraperiton
inject
normal
mice
frequenc
pbmc
ln
cell
increas
antibodi
treatment
surfac
stain
pbmc
treatment
antibodi
ng
significantli
increas
frequenc
cell
compar
normal
mice
ng
p
ng
p
ng
p
ng
p
ng
p
versu
pb
surfac
stain
ln
cell
treatment
antibodi
significantli
frequenc
ln
cell
compar
normal
mice
ng
p
ng
p
ng
p
ng
p
ng
p
versu
pb
fig
cytoplasm
frequenc
pbmc
treatment
antibodi
ng
alter
significantli
pbmc
cytoplasm
compar
normal
mice
ng
ng
ng
ng
ng
versu
pb
fig
cytoplasm
ln
cell
significantli
mice
treat
ng
antibodi
p
ng
antibodi
p
compar
normal
mice
treatment
ng
yield
signific
chang
compar
normal
mice
fig
cell
bd
mice
antibodi
ngday
administ
bd
mice
n
five
consecut
day
frequenc
express
surfac
pbmc
significantli
increas
compar
bd
mice
n
versu
p
ln
cell
frequenc
surfac
express
significantli
increas
antibodi
treatment
versu
p
fig
cytoplasm
pbmc
frequenc
express
treatment
antibodi
significantli
compar
pb
control
versu
p
howev
cytoplasm
ln
cell
treatment
antibodi
compar
pb
control
versu
p
fig
antibodi
treatment
improv
bd
symptom
bd
mice
day
initi
antibodi
treatment
list
improv
mice
provid
supplementari
materi
tabl
diseas
sever
score
bd
mice
chang
day
symptom
improv
antibodi
treatment
p
diseas
sever
score
also
significantli
vari
bd
mice
bd
mice
day
five
p
fig
figur
show
chang
symptom
treatment
antibodi
bd
mice
level
patient
activ
bd
pgml
higher
patient
inact
bd
pgml
p
healthi
control
individu
pgml
p
fig
studi
quantit
analyz
express
chemokin
receptor
pbmc
ln
cell
bd
mice
result
suggest
symptom
correl
frequenc
cell
percentag
cell
significantli
bd
mice
compar
normal
bdn
mice
cytokin
bd
mice
exhibit
signific
cell
compar
bd
mice
ligand
bd
mice
show
signific
cell
compar
bd
mice
ten
bd
mice
show
deterior
bd
symptom
antibodi
treatment
improv
bd
symptom
decreas
diseas
sever
score
cell
significantli
compar
bd
mice
treatment
bd
mice
colchicin
pentoxifyllin
significantli
cell
compar
pb
treatment
frequenc
cell
strongli
associ
symptom
bd
mice
chemokin
receptor
essenti
moder
leukocyt
traffick
inflammatori
diseas
may
strong
therapeut
target
varieti
shown
play
role
recruit
monocyt
cell
accord
activ
ligand
associ
develop
experiment
arthriti
rheumatoid
arthriti
effici
therapeut
target
mediat
regul
tumor
necrosi
howev
patient
bd
frequenc
cell
decreas
patient
activ
bd
normal
control
even
though
differ
statist
similarli
studi
also
show
frequenc
cell
bd
mice
compar
control
mice
express
report
infect
leishmania
infantum
correl
hsv
infect
express
show
consist
chemokin
express
report
arthrit
recruit
inflammatori
leukocyt
bind
affect
chronic
joint
neutral
antibodi
allevi
higher
serum
level
found
patient
activ
bd
patient
inact
stage
result
present
studi
demonstr
treatment
deterior
symptom
bd
mice
frequenc
cell
increas
express
exacerb
bd
symptom
known
mainli
express
monocyt
macrophag
cell
b
cell
one
key
cytokin
express
human
immun
respons
strong
inhibitor
cytokin
cytokin
suppress
cytokin
protect
host
tissu
patient
bd
polymorph
gene
variat
might
correl
insuffici
express
result
present
studi
show
frequenc
cell
bd
mice
compar
pb
control
also
synergist
increas
frequenc
cell
bd
mice
factor
stimul
enhanc
matur
dendrit
cell
play
role
recruit
circul
neutrophil
monocyt
lymphocyt
host
differ
type
inflammatori
immun
cell
dendrit
cell
monocyt
neutrophil
microglia
macrophag
modul
autoimmun
may
influenc
chronic
inflammatori
diseas
experiment
autoimmun
airway
also
enhanc
resist
viral
bacteri
patient
bd
transcript
howev
protein
express
serum
level
patient
bd
yet
elucid
accord
case
report
inject
recombin
human
induc
wound
heal
genit
ulcer
also
enhanc
data
demonstr
treatment
significantli
express
pbmc
ln
cell
develop
potent
antagonist
treatment
attenu
system
inflamm
studi
administ
bd
mice
confirm
correl
express
bd
inhibit
treatment
fail
inhibit
frequenc
surfac
cytoplasm
pbmc
ln
cell
bd
mice
normal
mice
inhibit
express
cytoplasm
pbmc
result
indic
treatment
fail
adequ
inhibit
cell
vivo
partli
explain
clinic
trial
inhibit
discontinu
conclus
studi
demonstr
frequenc
cell
close
correl
bd
symptom
express
cell
control
cytokin
ligand
even
though
bd
inflammatori
diseas
associ
immun
dysregul
treatment
singl
chemokin
chemokin
receptor
alon
contribut
immun
regul
result
control
system
symptom
bd
author
declar
conflict
interest
